Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Revance Therapeutics (RVNC) and Corbus Pharmaceuticals (CRBP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILDResearch Report), Revance Therapeutics (RVNCResearch Report) and Corbus Pharmaceuticals (CRBPResearch Report).

Gilead Sciences (GILD)

In a report issued on March 7, Brian Skorney from Robert W. Baird maintained a Hold rating on Gilead Sciences, with a price target of $63.00. The company’s shares closed last Tuesday at $59.54, close to its 52-week low of $58.90.

According to TipRanks.com, Skorney is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.3% and a 41.9% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $72.63 average price target, which is a 20.6% upside from current levels. In a report issued on February 22, Truist Financial also reiterated a Hold rating on the stock with a $75.00 price target.

See today’s best-performing stocks on TipRanks >>

Revance Therapeutics (RVNC)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Revance Therapeutics today and set a price target of $20.00. The company’s shares closed last Tuesday at $15.76.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 1.9% and a 38.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $23.67 average price target, implying a 59.7% upside from current levels. In a report issued on March 1, Needham also maintained a Buy rating on the stock with a $25.00 price target.

Corbus Pharmaceuticals (CRBP)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $3.00. The company’s shares closed last Tuesday at $0.34, close to its 52-week low of $0.30.

According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -8.3% and a 31.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Corbus Pharmaceuticals with a $2.25 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GILD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos